Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Safety Trial of Intracoronary Administration of Systemic Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis

NCT00124943 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00124943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00124943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Safety Trial of Intracoronary Administration of Systemic Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis
Lead sponsor
Celgene Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2005
Completion date
August 31, 2009
Enrollment
112 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

coronary restenosis